Gundeep Dhillon, MD
Critical Care Medicine · Palo Alto, CANPI 1285776161
Payments from drug & device makers
Across 16 payments — averaging $172.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Transmedics, Inc.$2K
- La Jolla Pharmaceutical Company$451
- Polarean, Inc.$344
- Kamada Ltd.$159
- Paragonix Technologies, Inc.$122
- Sunovion Pharmaceuticals Inc.$17
What the payments were for
- Travel & lodging$1,67761%
- Food & beverage$1,07839%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Transmedics, Inc. | 3 | $1,661 |
| La Jolla Pharmaceutical Company | 7 | $451 |
| Polarean, Inc. | 1 | $344 |
| Kamada Ltd. | 3 | $159 |
| Paragonix Technologies, Inc. | 1 | $122 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGAN CARE SYSTEM$1,661
- GIAPREZA$359
- XENOVIEW$344
- SherpaPak$122
- LIVERguard$122
- LUNGguard$122
- BaroGuard$122
- PancreasPak$122
How this compares
$2,755 in reported general payments places this provider in the 75th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Posaconazole | 181 | $155,880 |
| CresembaIsavuconazonium Sulfate | 17 | $127,684 |
| PrevymisLetermovir | 14 | $98,332 |
| Everolimus | 42 | $40,467 |
| Atovaquone | 65 | $33,790 |
| EliquisApixaban | 31 | $29,572 |
| Valganciclovir Hcl | 159 | $28,035 |
| Itraconazole | 98 | $27,396 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,970 |
| JanuviaSitagliptin Phosphate | 16 | $8,690 |
| Mycophenolate Mofetil | 37 | $5,666 |
| Tacrolimus | 81 | $5,345 |
| Clotrimazole | 80 | $3,175 |
| Acyclovir | 255 | $2,788 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,296 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Palo Alto
- Ware KuschnerPalo Alto$40K
- Juliana BarrPalo Alto$27K
- Rafael LupercioRedding$14.6M
- Timothy AlbertsonSacramento$7.6M
- Carolyn CalfeeSan Francisco$5M
- Bassam YaghmourOrange$4.4M
- Cedric Franklin RutlandRiverside$3.2M
- Alex HakimLos Angeles$946K
- Praveen AkuthotaSan Diego$841K
- Wael El MaraachliSan Diego$751K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.